Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer

Mark P. Simons; William M. Nauseef; Thomas S. Griffith

doi:10.1007/s12026-007-0084-1

Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer

Mark P. Simons, William M. Nauseef, Thomas S. Griffith

Urology

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.

Original language	English (US)
Pages (from-to)	79-93
Number of pages	15
Journal	Immunologic Research
Volume	39
Issue number	1-3
DOIs	https://doi.org/10.1007/s12026-007-0084-1
State	Published - Nov 2007

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the University of Iowa Infectious Diseases Postdoctoral Training Grant (MPS), grant AI034879–19 from the National Institutes of Health (WMN), Carver Medical Research Initiative Grant administered through the University of Iowa Carver College of Medicine (TSG), and grant CA109446 from the National Cancer Institute (TSG).

Keywords

BCG
Mycobacterium
Neutrophil
PMN
TRAIL

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/s12026-007-0084-1

Find It

Find It at U of M Libraries

Cite this

@article{d2ede81fb81e404895885308b191c4c5,

title = "Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer",

abstract = "Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.",

keywords = "BCG, Mycobacterium, Neutrophil, PMN, TRAIL",

author = "Simons, {Mark P.} and Nauseef, {William M.} and Griffith, {Thomas S.}",

note = "Funding Information: Acknowledgments This work was supported by the University of Iowa Infectious Diseases Postdoctoral Training Grant (MPS), grant AI034879–19 from the National Institutes of Health (WMN), Carver Medical Research Initiative Grant administered through the University of Iowa Carver College of Medicine (TSG), and grant CA109446 from the National Cancer Institute (TSG).",

year = "2007",

month = nov,

doi = "10.1007/s12026-007-0084-1",

language = "English (US)",

volume = "39",

pages = "79--93",

journal = "Immunologic Research",

issn = "0257-277X",

publisher = "Humana Press",

number = "1-3",

}

TY - JOUR

T1 - Neutrophils and TRAIL

T2 - Insights into BCG immunotherapy for bladder cancer

AU - Simons, Mark P.

AU - Nauseef, William M.

AU - Griffith, Thomas S.

N1 - Funding Information: Acknowledgments This work was supported by the University of Iowa Infectious Diseases Postdoctoral Training Grant (MPS), grant AI034879–19 from the National Institutes of Health (WMN), Carver Medical Research Initiative Grant administered through the University of Iowa Carver College of Medicine (TSG), and grant CA109446 from the National Cancer Institute (TSG).

PY - 2007/11

Y1 - 2007/11

N2 - Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.

AB - Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.

KW - BCG

KW - Mycobacterium

KW - Neutrophil

KW - PMN

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=35348880300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348880300&partnerID=8YFLogxK

U2 - 10.1007/s12026-007-0084-1

DO - 10.1007/s12026-007-0084-1

M3 - Review article

C2 - 17917057

AN - SCOPUS:35348880300

SN - 0257-277X

VL - 39

SP - 79

EP - 93

JO - Immunologic Research

JF - Immunologic Research

IS - 1-3

ER -

Neutrophils and TRAIL: Insights into BCG immunotherapy for bladder cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this